US Patent No: 8,163,888

Number of patents in Portfolio can not be more than 2000

Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates

Stats

ALSO PUBLISHED AS: 20080114153
ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
IMMUNOGEN, INC.WALTHAM, MA89

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Blattler, Walter A Brookline, MA 30 570
Chari, Ravi V J Newton, MA 66 387
Steeves, Rita M Stoneham, MA 6 6

Cited Art

Patent Info (Count) # Cites Year
 
TAKEDA CHEMICAL INDUSTRIES, LTD. (17)
4,265,814 Matansinol 3-n-hexadecanoate 22 1979
4,248,870 Maytansinoids and use 24 1979
4,256,746 Dechloromaytansinoids, their pharmaceutical compositions and method of use 26 1979
4,260,608 Maytansinoids, pharmaceutical compositions thereof and methods of use thereof 23 1979
4,294,757 20-O-Acylmaytansinoids 27 1980
4,322,348 Maytansinoids 27 1980
4,317,821 Maytansinoids, their use and pharmaceutical compositions thereof 21 1980
4,307,016 Demethyl maytansinoids 28 1980
4,308,268 Maytansinoids, pharmaceutical compositions thereof and method of use thereof 23 1980
4,308,269 Maytansinoids, pharmaceutical compositions thereof and method of use thereof 23 1980
4,309,428 Maytansinoids 23 1980
4,331,598 Maytansinoids 29 1980
4,362,663 Maytansinoid compound 26 1980
4,364,866 Maytansinoids 27 1980
4,361,650 Fermentation process of preparing demethyl maytansinoids 27 1981
4,371,533 4,5-Deoxymaytansinoids, their use and pharmaceutical compositions thereof 26 1981
4,424,219 9-Thiomaytansinoids and their pharmaceutical compositions and use 29 1982
 
GENENTECH, INC. (13)
6,949,245 Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies 31 2000
2003/0086,924 Treatment with anti-ErbB2 antibodies 23 2002
2004/0013,667 Treatment with anti-ErbB2 antibodies 21 2003
7,862,817 Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies 7 2005
7,618,631 Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs 7 2005
7,498,030 Treatment with anti-ErbB2 antibodies and anti-hormonal compounds 10 2005
7,501,122 Treatment with anti-ErbB2 antibody combinations 10 2005
7,485,302 Treatment with anti-ErbB2 antibodies and chemotherapeutic agents 10 2006
7,537,931 Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies 10 2006
2006/0216,285 Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies 19 2006
2007/0184,055 TREATMENT WITH ANTI-ERBB2 ANTIBODIES 23 2007
2007/0269,429 TREATMENT WITH ANTI-ERBB2 ANTIBODIES 23 2007
2011/0129,464 HUMANIZED ANTI-ERBB2 ANTIBODIES AND TREATMENT WITH ANTI-ERBB2 ANTIBODIES 7 2010
 
IMMUNOGEN, INC. (8)
5,208,020 Cytotoxic agents comprising maytansinoids and their therapeutic use 98 1992
5,416,064 Cytotoxic agents comprising maytansinoids and their therapeutic use 69 1992
6,333,410 Process for the preparation and purification of thiol-containing maytansinoids 44 2000
7,303,749 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents 6 2000
7,097,840 Methods of treatment using anti-ErbB antibody-maytansinoid conjugates 39 2001
6,441,163 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents 47 2001
7,368,565 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents 1 2002
7,276,497 Cytotoxic agents comprising new maytansinoids 8 2004
 
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (2)
4,313,946 Chemotherapeutically active maytansinoids from Trewia nudiflora 28 1981
4,315,929 Method of controlling the European corn borer with trewiasine 27 1981
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
6,531,131 Conjugate vaccine for Neisseria meningitidis 14 2000
 
RESEARCH DEVELOPMENT FOUNDATION (1)
7,754,211 Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens 6 2004
 
STANDARD OIL COMPANY (INDIANA) (1)
4,450,254 Impact improvement of high nitrile resins 26 1982
 
UNIVERSITY HOSPITAL, THE (1)
5,679,648 Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides 13 1994

Patent Citation Ranking

Forward Cites

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Oct 24, 2015
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 24, 2019
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 24, 2023
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00